# US 2013/0210710 A1 · Treatment of hiv

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0210710 A1
- Document ID: US20130210710A1
- Status: Published application
- Kind: A1
- Application number: 13/693,174
- Filed: 2012-12-04
- Published: 2013-08-15
- Earliest claimed: 2006-01-06
- Assignees: Aimsco Limited
- Inventors: Deirdre McIntosh
- Web page: https://patentgrep.com/patent/US20130210710A1

## CPC

- A61K 38/2228: {Corticotropin releasing factor [CRF] (Urotensin)}
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/1709: {from mammals}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/2066: {IL-10}
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61K 38/33: derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K 38/34: Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
- A61K 38/35: Corticotropin [ACTH]
- A61P 31/18: for HIV
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

We describe methods of treatment of HIV using proopiomelanocortin (POMC) and corticotropin releasing factor (CRF) peptides and their products, as well as uses of such peptides in the preparation of medicaments.

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

A method of treatment of HIV comprising administering a corticotropin releasing factor (CRF) peptide to a patient.

### Claim 15 (depends on 14)

The method of claim 14, wherein one or more of the following effects is achieved: a reduction in viral load; an increase in CD4 cells; or an increase in CD8 cells.

### Claim 16 (depends on 14)

The method of claim 14 wherein the CRF is non-human CRF.

### Claim 17 (depends on 16)

The method of claim 16 wherein the CRF is goat CRF.

### Claim 18 (depends on 14)

The method of claim 14, and further comprising administering a POMC peptide or a POMC product.

### Claim 19 (depends on 18)

The method of claim 18, and further comprising administering two or more of alpha, beta, and gamma melanocyte stimulating hormone (MSH); adrenocorticotrophin (ACTH); beta and gamma lipotropin (LPH); and beta endorphin.
